BJDXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Bluejay Diagnostics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.70−0.05 (-6.46%)
Close on Oct 19, 2026
- Market cap
- $1.45M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 32.5% | -117.0% | |
| Return on assets | – | – | -99.4% | |
| Current ratio | – | – | 4.88 | |
| Interest coverage | – | -20.2× | -8287.2× | |
| Diluted shares | – | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Bluejay Diagnostics generated $34.30M from operations and spent $2.41M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$34.30M
Used
$2.41M
Capital expenditure$2.41M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3733.1%
×Asset turnover0.01×
×Equity multiplier1.08×
=Return on equity, FY2022-58.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -3733.1% | 0.01× | 1.08× | -58.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$6.85M
- Cash generatingOperating cash flow above zero-$6.05M
- Return on assets improvedROA up on the prior year-158.5% → -102.9%
- Earnings backed by cashOperating cash flow above net income-$6.05M vs -$6.85M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.05 → 4.88
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –